Ronald C. Chen

Dr. Ronald C. Chen


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2012 in JAMA
Verified
Journal Article
Open access
PDF file
GGGregg H. Goldin
Gregg H. Goldin
NSNathan C. Sheets
Nathan C. Sheets
AMAnne-Marie Meyer
Anne-Marie Meyer
YWYang Wu
Yang Wu
YCYunKyung Chang
YunKyung Chang
RCRonald C. Chen
Ronald C. Chen
Prostate cancer is the most common malignancy in men, with more than 200 000 diagnoses and 30 000 deaths per year.1 Recent advances in technology have led to costlier treatments such as minimally invasive radical prostatectomy, intensity-modulated radiation therapy (IMRT), and proton therapy. The adoption of these technologies resulted in a $350 million increase in health care expenditures in 2005 alone.2 The Institute of Medicine, Agency for Healthcare Research and Quality, Secretary of the Department of Health and Human Services, and others have called for comparative effectiveness research of localized prostate cancer treatments,3-5 which is especially relevant for radiation therapy, for which IMRT has gradually replaced the older technique of conformal radiation therapy during the past 10 years. More recently, there has been a substantial increase in the number of proton facilities built, and direct-to-consumer advertising is likely to lead to an increase in its use.6-8 The clinical benefit from these newer treatments is unproven, and comparative effectiveness research examining different radiation techniques is lacking. Given these trends in use, multiple recent reports have specifically called for research on proton therapy.9

29 April 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
RCRonald C. Chen
Ronald C. Chen
KHKevin Haynes
Kevin Haynes
SDSimo Du
Simo Du
JBJohn Barron
John Barron
AKAaron J. Katz
Aaron J. Katz
Across the US, the COVID-19 pandemic influenced health care rapidly and dramatically in 2020. As cases rose across the country, many states began to implement stay-at-home orders. In addition, the Centers for Disease Control and Prevention started to issue guidance to help individuals reduce exposure, and particular attention was directed toward older adults and those with comorbidities, who are at higher risk for developing severe complications from COVID-19. As a result, hospitals and clinics across the country dramatically reduced nonemergency clinical appointments. These changes likely had a direct and negative influence on cancer screening.1-5

21 March 2017 in JAMA
Verified
Journal Article
Open access
PDF file
RCRonald C. Chen
Ronald C. Chen
RBRamsankar Basak
Ramsankar Basak
AMAnne-Marie Meyer
Anne-Marie Meyer
TKTzy-Mey Kuo
Tzy-Mey Kuo
WCWilliam R. Carpenter
William R. Carpenter
PGPaul A. Godley
Paul A. Godley
The comparative effectiveness of contemporary treatment options for localized prostate cancer is one of the highest priority research questions according to the National Academy of Medicine (previously the Institute of Medicine).1 Because patients with prostate cancer often have extended life expectancy, the quality-of-life (QOL) effects of different treatment options is a central consideration for many men in their decision-making process.

1 October 2014 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
TRTrevor J. Royce
Trevor J. Royce
LHLaura H. Hendrix
Laura H. Hendrix
WSWilliam A. Stokes
William A. Stokes
IAIan M. Allen
Ian M. Allen
RCRonald C. Chen
Ronald C. Chen
Healthy People 2020, an initiative released by the US Department of Health and Human Services, defined our nation’s current public health priorities in prevention and health promotion.1,2 In the context of cancer, Healthy People aims to increase the proportion of individuals who receive screening consistent with the US Preventive Services Task Force (USPSTF)’s evidence-based guidelines. These guidelines include not only indications for cancer screening but also cessation of screening for some conditions when there is no evidence for net benefit or when evidence suggests screening may lead to net harm. Healthy People specifically recommends using data from the National Health Interview Survey (NHIS) to quantify progress in achieving these goals.2

27 June 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
YCYing Cao
Ying Cao
RCRonald C. Chen
Ronald C. Chen
AKAaron J Katz
Aaron J Katz
Clinical studies are often limited by resources available, which results in constraints on sample size. We use simulated data to illustrate study implications when the sample size is too small. Using 2 theoretical populations each with N = 1000, we randomly sample 10 from each population and conduct a statistical comparison, to help make a conclusion about whether the 2 populations are different. This exercise is repeated for a total of 4 studies: 2 concluded that the 2 populations are statistically significantly different, while 2 showed no statistically significant difference. Our simulated examples demonstrate that sample sizes play important roles in clinical research. The results and conclusions, in terms of estimates of means, medians, Pearson correlations, chi-square test, and P values, are unreliable with small samples.

1 October 2012 in Seminars in Radiation Oncology
Verified
Journal Article
Closed access
RCRonald C. Chen
Ronald C. Chen
TRTrevor J. Royce
Trevor J. Royce
MEMartine Extermann
Martine Extermann
BRBryce B. Reeve
Bryce B. Reeve